Estrogen receptor beta signaling through phosphatase and tensin homolog/phosphoinositide 3-kinase/Akt/glycogen synthase kinase 3 down-regulates blood-brain barrier breast cancer resistance protein.
Breast cancer resistance protein (BCRP) is an ATP-driven efflux pump at the blood-brain barrier that limits central nervous system pharmacotherapy. Our previous studies showed rapid loss of BCRP transport activity in rat brain capillaries exposed to low concentrations of 17-beta-estradiol (E2); this occurred without acute change in BCRP protein expression. Here, we describe a pathway through which sustained, extended exposure to E2 signals down-regulation of BCRP at the blood-brain barrier. Six-hour exposure of isolated rat and mouse brain capillaries to E2 reduced BCRP transport activity and BCRP monomer and dimer expression. Experiments with brain capillaries from estrogen receptor (ER)alpha and ERbeta knockout mice and with ER agonists and antagonists showed that E2 signaled through ERbeta to down-regulate BCRP expression. In rat brain capillaries, E2 increased unphosphorylated, active phosphatase and tensin homolog (PTEN); decreased phosphorylated, active Akt; and increased phosphorylated, active glycogen synthase kinase (GSK)3. Consistent with this, inhibition of phosphoinositide 3-kinase (PI3K) or Akt decreased BCRP activity and protein expression, and inhibition of PTEN or GSK3 reversed the E2 effect on BCRP. Lactacystin, a proteasome inhibitor, abolished E2-mediated BCRP down-regulation, suggesting internalization followed by transporter degradation. Dosing mice with E2 reduced BCRP activity in brain capillaries within 1 h; this reduction persisted for 24 h. BCRP protein expression in brain capillaries was unchanged 1 h after E2 dosing but was substantially reduced 6 and 24 h after dosing. Thus, E2 signals through ERbeta, PTEN/PI3K/Akt/GSK3 to stimulate proteasomal degradation of BCRP. These in vitro and in vivo findings imply that E2-mediated down-regulation of blood-brain barrier BCRP has the potential to increase brain uptake of chemotherapeutics that are BCRP substrates.
Hartz
A M S
AM
Department of Biochemistry and Molecular Biology, Medical School Duluth, University of Minnesota, Duluth, Minnesota 55812, USA.
Madole
E K
EK
Miller
D S
DS
Bauer
B
B
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000096:biosynthesis*; D000818:Animals; D001812:Blood-Brain Barrier / Q000378:metabolism*; D002196:Capillaries / Q000378:metabolism; D015536:Down-Regulation; D004958:Estradiol / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000235:genetics; D047629:Estrogen Receptor beta / Q000819:agonists / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D005260:Female; D038362:Glycogen Synthase Kinase 3 / Q000502:physiology*; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D051059:PTEN Phosphohydrolase / Q000502:physiology*; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D010744:Phosphoric Monoester Hydrolases / Q000502:physiology*; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015398:Signal Transduction
D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; C501412:Abcg2 protein, mouse; C489249:Abcg2 protein, rat; D047628:Estrogen Receptor alpha; D047629:Estrogen Receptor beta; D004958:Estradiol; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt; D038362:Glycogen Synthase Kinase 3; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C487757:Pten protein, mouse; C487216:Pten protein, rat; D046988:Proteasome Endopeptidase Complex
J Cereb Blood Flow Metab. 2010 Jul;30(7):1373-83
20197783
FASEB J. 2008 Aug;22(8):2723-33
18474546
Clin Cancer Res. 2007 Nov 1;13(21):6440-9
17975156
Pharm Res. 2009 Feb;26(2):480-7
18841445
Life Sci. 2006 Mar 27;78(18):2131-45
16442130
Endocr Rev. 1993 Aug;14(4):459-79
8223341
Mol Pharmacol. 2006 Feb;69(2):462-70
16278373
Fundam Clin Pharmacol. 2004 Oct;18(5):547-57
15482376
Drug Metab Dispos. 2009 May;37(5):946-55
19225039
Endocrinology. 2003 May;144(5):2055-67
12697714
Proc Natl Acad Sci U S A. 1993 Dec 1;90(23):11162-6
8248223
J Biol Chem. 2009 Oct 16;284(42):28579-89
19706605
Biochem Biophys Res Commun. 2002 May 17;293(4):1273-8
12054514
J Cereb Blood Flow Metab. 2010 Oct;30(10):1742-55
20216549
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5
10200246
Pharm Res. 2008 Feb;25(2):444-52
17823853
Eur J Endocrinol. 2003 Mar;148(3):281-92
12611608
Neuroreport. 2002 Nov 15;13(16):2059-63
12438926
J Biol Chem. 2000 May 26;275(21):15917-25
10748167
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13162-7
16938840
Cancer Res. 2005 Jan 15;65(2):596-604
15695404
Mol Pharmacol. 2005 May;67(5):1765-71
15722455
Drug Metab Dispos. 2009 Feb;37(2):439-42
19056914
Front Neuroendocrinol. 2008 Jun;29(3):375-85
18439661
J Pharmacol Exp Ther. 2010 Jun;333(3):788-96
20304939
Biochem Biophys Res Commun. 2005 Jan 7;326(1):181-7
15567169
Blood. 2006 Jul 15;108(2):678-84
16543472
Trends Pharmacol Sci. 2006 Jan;27(1):17-24
16337012
J Biol Chem. 2001 Feb 2;276(5):3459-67
11044445
J Pharmacol Exp Ther. 2009 Sep;330(3):956-63
19491323
J Steroid Biochem Mol Biol. 2001 Jul;78(1):33-40
11530282
Steroids. 2010 Aug-Sep;75(8-9):565-9
19778547
J Neurobiol. 1998 Sep 5;36(3):357-78
9733072
J Biol Chem. 2004 May 7;279(19):19781-9
15001581
J Clin Endocrinol Metab. 2003 Oct;88(10):5017-26
14557489
Oncology. 2006;71(5-6):446-55
17878748
Mol Pharmacol. 2007 Mar;71(3):667-75
17132686
Mol Pharmacol. 2003 Dec;64(6):1452-62
14645676
J Neurosci. 2010 Jan 27;30(4):1417-25
20107068
Cell Stem Cell. 2009 Mar 6;4(3):226-35
19265662
J Mammary Gland Biol Neoplasia. 2009 Mar;14(1):3-9
19224345
Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1295-304
17082346
Mol Pharmacol. 2004 Sep;66(3):387-94
15322229